Body Composition and Psychosocial Factors in ICI-Treated Cancer Patients

Study of Body Composition and Well-Being Factors in Cancer Patients on Immunotherapy

Recruiting
18 years or above
All
Phase N/A
200 participants needed
1 Location

Brief description of study

Evaluation of the effects of body composition, psychosocial factors, and drug-related problems on clinical progression (such as toxicity, treatment response, and quality of life) in cancer patients treated with immune checkpoint inhibitors

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Cancer, Psychosocial Functioning, Treatment Side Effects, Cachexia
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

  • Aged 18 years or older
  • Having undergone a CT scan (at the L3 level) prior to treatment
  • No severe mental disorder and able to communicate effectively
  • Provided written informed consent

Exclusion Criteria:

  • Did not provide written informed consent
  • Patients deemed unsuitable by the physician

The purpose of this research study is to learn how body composition (how much muscle and fat you have), psychosocial factors (mental and social well-being), and medicine-related problems relate to clinical progression in adults with cancer who are treated with immune checkpoint inhibitors (a type of immunotherapy). The study will look at outcomes such as treatment side effects, how the cancer responds to treatment, and quality of life.

Participants will be adults with cancer who are being treated with immune checkpoint inhibitors. Participants will have already had a CT scan that includes a specific area of the lower back (the L3 level) before starting treatment. The study team will use information about body composition, psychosocial factors, and drug-related problems to evaluate how these factors relate to side effects, treatment response, and quality of life.

Who can participate:
Adults with cancer may be able to participate if they:

  • Are age 18 or older
  • Have had a CT scan at the L3 level before starting treatment
  • Do not have a severe mental disorder and can communicate effectively

Updated on 24 Mar 2026. Study ID: SBA 25/672

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team